Want to see AU:SHG full AI Analyst Report?
Top Page
Singular Health Group Ltd
(Sydney:SHG)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.17
▼(-35.38% Downside)
Action:Reiterated
Date:06/27/26
The score is primarily driven by weak financial performance (persistent losses, deteriorating 2025 revenue, and ongoing cash burn), which raises funding and execution risk. Technicals add pressure as the stock trades below all key moving averages with negative MACD. Valuation offers limited support because the company is loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Low reported leverage (2025)
The 2025 balance sheet shows zero debt and a large equity base, reducing near-term refinancing risk and providing financial flexibility. For the next 2-6 months this strengthens the company’s ability to fund operations or pursue strategic options without immediate debt pressure.
Negative Factors
Persistent unprofitability
Consistent losses and a negative gross profit in 2025 signal structural unprofitability. This undermines internal funding capacity, forces reliance on external capital, and limits the company's ability to reinvest in growth or scale margins absent a sustained change in revenue or cost structure.
Read all positive and negative factors
Positive Factors
Negative Factors
Low reported leverage (2025)
The 2025 balance sheet shows zero debt and a large equity base, reducing near-term refinancing risk and providing financial flexibility. For the next 2-6 months this strengthens the company’s ability to fund operations or pursue strategic options without immediate debt pressure.
Read all positive factors
Singular Health Group Ltd (SHG) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$57.82M
Dividend YieldN/A
Average Volume (3M)1.03M
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.02
Shares Outstanding323,773,100
10 Day Avg. Volume889,327
30 Day Avg. Volume1,029,223
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)6.82
Price to Sales (P/S)160.16
P/FCF Ratio-37.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Singular Health Group Ltd Business Overview & Revenue Model
Company Description
Singular Health Group Ltd operates as a medical technology enterprise dedicated to developing and commercializing a volumetric rendering platform (VRP). This advanced platform facilitates the three-dimensional and virtual reality presentation of a...
How the Company Makes Money
null...
Singular Health Group Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 961.53K | 557.61K | 934.07K | 28.12K | 54.03K | 193.64K |
| Gross Profit | -2.01M | -86.22K | 516.36K | -3.58M | -2.11M | -1.62M |
| EBITDA | -8.14M | -6.27M | -2.58M | -4.52M | -5.65M | -2.86M |
| Net Income | -7.43M | -6.38M | -4.92M | -5.39M | -5.99M | -4.46M |
Balance Sheet | ||||||
| Total Assets | 12.55M | 14.21M | 2.35M | 3.00M | 2.14M | 5.43M |
| Cash, Cash Equivalents and Short-Term Investments | 11.06M | 13.68M | 1.45M | 691.51K | 1.14M | 4.14M |
| Total Debt | 113.71K | 0.00 | 218.45K | 2.51M | 85.66K | 147.59K |
| Total Liabilities | 856.60K | 1.11M | 909.59K | 2.94M | 391.50K | 345.10K |
| Stockholders Equity | 11.69M | 13.10M | 1.44M | 61.89K | 1.75M | 5.08M |
Cash Flow | ||||||
| Free Cash Flow | -4.38M | -2.37M | -2.51M | -2.49M | -2.92M | -2.22M |
| Operating Cash Flow | -4.23M | -2.34M | -2.44M | -2.46M | -2.91M | -1.91M |
| Investing Cash Flow | -8.49M | 88.14K | -3.56K | -635.21K | -17.12K | -610.57K |
| Financing Cash Flow | 6.36M | 14.48M | 3.21M | 2.65M | -69.25K | 6.52M |
Singular Health Group Ltd Technical Analysis
Negative
0.26
Price Trends
0.21
Negative
0.22
Negative
0.24
Negative
Market Momentum
>-0.01
Positive
38.83
Neutral
30.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SHG, the sentiment is Negative. The current price of 0.26 is above the 20-day moving average (MA) of 0.20, above the 50-day MA of 0.21, and above the 200-day MA of 0.24, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.83 is Neutral, neither overbought nor oversold. The STOCH value of 30.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:SHG.
Singular Health Group Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$128.98M | 32.76 | 4.37% | ― | 36.43% | ― | |
55 Neutral | AU$69.33M | -6.57 | -23.86% | ― | -11.45% | -97.22% | |
52 Neutral | AU$45.06M | -7.75 | -14.19% | ― | 0.03% | -5.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$20.90M | -2.76 | -1009.84% | ― | 13.69% | 7.57% | |
42 Neutral | AU$57.82M | -8.12 | -59.96% | ― | ― | ― |
* Healthcare Sector Average
AU:SHG
Singular Health Group Ltd
0.19
-0.18
-48.65%
AU:M7T
Mach7 Technologies
0.29
-0.05
-13.64%
AU:BMT
Beamtree Holdings Ltd
0.16
-0.10
-38.00%
AU:ALC
Alcidion Group Limited
0.10
>-0.01
-5.00%
AU:PCK
PainChek Ltd
0.10
-0.35
-78.44%
Singular Health Group Ltd Corporate Events
Singular Health Raises Capital via Option Exercise and Issues Cleansing Notice
Jun 28, 2026
Singular Health Group has strengthened its capital base by issuing 2,571,222 fully paid ordinary shares following the exercise of an equal number of unlisted options at $0.10 each, raising $257,122.20. The company has applied to quote the new shar...
Singular Health Seeks Quotation for Additional ASX Shares
Jun 28, 2026
Singular Health Group Ltd has applied for the quotation of 2,571,222 new ordinary fully paid shares on the Australian Securities Exchange. The securities, issued on 26 June 2026, arise from the exercise of options or conversion of other securities...
Singular Health Director Increases Stake Through Option Exercise
Jun 24, 2026
Singular Health Group has disclosed a change in director Denning Chong’s interests following the exercise of unlisted options held through an associated entity. The transaction converted 1,818,182 unlisted options priced at $0.10 into the sa...
Singular Health Raises Capital via Option Exercises and Issues Cleansing Notice
Jun 22, 2026
Singular Health Group has raised a total of $432,272.70 through the exercise of unlisted options, issuing 4,460,227 new fully paid ordinary shares at strike prices of $0.10 and $0.08. The company has applied to have these shares quoted on the ASX ...
Singular Health Seeks Quotation of 4.46 Million New ASX Shares
Jun 22, 2026
Singular Health Group Ltd, an ASX-listed health technology company trading under ticker SHG, develops digital healthcare and medical imaging solutions for clinical and allied health users. The company targets technology-enabled healthcare workflow...
Singular Health Raises Capital via Option Exercise and Confirms Regulatory Compliance
May 1, 2026
Singular Health Group Ltd has issued 363,636 fully paid ordinary shares following the exercise of an equivalent number of unlisted options at $0.10 each, raising $36,636.60 in new capital. The company has confirmed that the shares were issued with...
Singular Health Group Seeks ASX Quotation for 363,636 New Shares
May 1, 2026
Singular Health Group Ltd has applied to the ASX for quotation of 363,636 new fully paid ordinary shares under code SHG, with an issue date of 1 May 2026. The new shares arise from the exercise or conversion of existing options or other convertibl...
Singular Health expands U.S. deployments as 3D imaging platform gains traction
Apr 27, 2026
Singular Health Group reported a quarter of consolidation and expansion, advancing commercial deployments and education partnerships, particularly in the U.S. healthcare and academic markets. The company aims to deliver scalable, interoperable ima...
Singular Health Secures US$500,000 as PNS Expands Use of 3DICOM MD
Apr 21, 2026
Singular Health Group has received US$500,000 from U.S.-based Provider Network Solutions under a binding enterprise agreement linked to the deployment of its 3DICOM MD medical imaging licences. The payment follows the rollout of an additional 500 ...
Singular Health Raises Capital Through Exercise of Unlisted Options
Apr 9, 2026
Singular Health Group has issued 272,728 new fully paid ordinary shares following the exercise of an equivalent number of unlisted options priced at $0.10 and expiring in June 2026, raising $27,272.80 in additional capital. The company confirmed t...
Singular Health Seeks ASX Quotation for Additional 272,728 Shares
Apr 9, 2026
Singular Health Group Ltd has applied to the ASX for quotation of 272,728 new fully paid ordinary shares under the code SHG, with an issue date of 9 April 2026. The securities arise from the exercise or conversion of existing options or other conv...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.